About This Article
Evaluation of postprandial glycemic excursions in patients with type 1 diabetes with three prandial insulins: VIAject™ (Linjeta™), an ultra-fast insulin (UFI); insulin lispro (LIS); and regular human insulin (RHI).
Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection
Article Authors: Lutz Heinemann, Marcus Hompesch, Frank Flacke, Patrick Simms, Rody Pohl, Kerstin Albus, Andreas Pfützner, Solomon Steiner
